Based on these findings, inhibiting the CCR2 and CCR5 pathways could benefit patients in both early and late stages of infection; optimal administration of CVC during several phases of the SARS-CoV-2 infection may attenuate or prevent inflammatory consequences of COVID-19 and prove beneficial by avoiding excessive monocyte recruitment (Fig 2) [63,64]. This evidence concerns the gene CCR2 and infection.